Immuneering Corporation Presents Promising Survival Data for Atebimetinib Plus Chemotherapy in First-Line Pancreatic Cancer
Immuneering Corporation has reported promising clinical data for its drug, atebimetinib, in combination with chemotherapy for first-line pancreatic cancer. Interim results from a Phase 2a study show a 94% overall survival rate at six months and 86% at nine months, significantly higher than standard treatments. The therapy was well-tolerated and will proceed to further studies in pancreatic and lung cancer. The median overall survival has not yet been reached, with a median follow-up of nine months.
Immuneering Corporation has presented updated clinical data on its lead candidate, atebimetinib, in combination with modified gemcitabine and nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer. According to interim results from a Phase 2a study (N=34), the combination therapy demonstrated a 94% overall survival (OS) rate at six months and an 86% OS rate at nine months, as of the August 26, 2025 data cutoff. These rates compare to historical data for standard-of-care gemcitabine and nab-paclitaxel, which showed 67% and approximately 47% OS at six and nine months, respectively. The median OS for the study cohort has not yet been reached, with a median follow-up of nine months. The company also reported that the combination therapy was favorably tolerated and is advancing to further clinical studies in pancreatic and lung cancer. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
